Physician profile
Michael Trimba
NPI 1396725081
$3,202.62
in general payments reported to CMS, 2019-2025
23 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $844 · 2020: $421 · 2021: $615 · 2022: $300 · 2023: $711 · 2024: $154 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,022.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $390.33 | 2019-2024 | |
| Fidia Pharma USA INC. | $337.25 | 2019-2025 | Triluron, Hymovis, Hyalgan |
| Pacira Therapeutics, INC. | $328.00 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $316.46 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $301.15 | 2020-2023 | Ztlido |
| Horizon Therapeutics Plc | $271.92 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $244.58 | 2019-2025 | Relistor |
| Kowa Pharmaceuticals America, INC. | $199.47 | 2022-2023 | Seglentis |
| Zimmer Biomet Holdings, INC. | $98.52 | 2019-2023 | Gel-One Cross-Linked Hyaluronate |
| Sentynl Therapeutics, INC. | $92.84 | 2019 | |
| Ferring Pharmaceuticals INC. | $92.26 | 2019-2021 | |
| Assertio Therapeutics, INC. | $88.82 | 2019 | |
| Pfizer INC. | $59.09 | 2021 | |
| Bioventus LLC | $57.57 | 2019-2023 | Gelsyn-3 |
| Astrazeneca Pharmaceuticals Lp | $55.41 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $54.31 | 2025 | Prolate, Nalocet, Tanlor |
| Pacira Pharmaceuticals Incorporated | $48.00 | 2023-2025 | Zilretta, Iovera |
| Depuy Synthes Sales INC. | $46.40 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $44.00 | 2023-2025 | Horizant, Horizant |
| Redhill Biopharma INC. | $24.65 | 2021 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Abbvie INC. | $16.84 | 2021 | |
| Allergan, INC. | $13.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Trimba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.